The Latest Cardiac and Vascular News
Boston Scientific decides it’s too risky and that there are “bigger” problems to deal with. Boston Scientific to end Renuvia bioresorbable coronary stent program JULY 31, 2017 BY FINK DENSFORD, MassDevice Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent […]
Boston Scientific warns on fluke S-ICD death JULY 28, 2017 BY BRAD PERRIELLO , MassDevice Boston Scientific (NYSE:BSX) last month alerted physicians after learning of a fluke incident involving its S-ICD pacemaker, in which a patient died when the device’s memory was corrupted by […]
MARLBOROUGH, Mass., July 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on an operational basis (excludes the impact […]
NEWS PROVIDED BY Boston Scientific Corporation 08:30 ET MARLBOROUGH, Mass., July 5, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at 8:00 a.m. EDT. The call will […]
MARLBOROUGH, Mass., June 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman of the Board […]
MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features […]
MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago […]
MARLBOROUGH, Mass., April 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on a reported and operational […]
MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The […]
